Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the period, the company expects revenues of ¥1,150,000 million, Core operating profit of ¥440,000 million, Core net income of ¥312,500 million and Core earnings per share of ¥190.00.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5,094 JPY | +1.35% | +4.99% | -4.64% |
01/05 | Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation | MT |
25/04 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.64% | 54.81B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- 4519 Stock
- News Chugai Pharmaceutical Co., Ltd
- Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022